Daily Archives: January 7, 2013

How to Add a Custom Track onto the UCSC Genome Browser
How to Add a Custom Track onto the UCSC Genome Browser

By: David G

More here:
How to Add a Custom Track onto the UCSC Genome Browser - Video

How to Add Minimal and Maximal breakpoints on the UCSC Genome Browser
How to Add Minimal and Maximal breakpoints on the UCSC Genome Browser

By: David G

Read more here:
How to Add Minimal and Maximal breakpoints on the UCSC Genome Browser - Video

Human Genome Project
After reading about this and listening to my friend, I wanted to share this information with you my subs and friends. I didn #39;t know exactley what it was. But now it think everyone should know. If you know great , if you don #39;t i wanted to share. http://www.ornl.gov My Sub and friend SuperDeltaBravo1 Gave Permission to use her video and information as stated. I HEREBY GRANT EVERYONE WRITTEN PERMISSION TO DOWNLOAD RE-UPLOAD TO YOUR CHANNELS ALL OTHER SOCIAL MEDIA OUTLETS. If you would like to donate for my work the link is below. thank You For Your Blessings...J https

By: J7409

More:
Human Genome Project - Video

Jan. 7, 2013 Fox Chase Cancer Center, a National Cancer Institute-designated Comprehensive Cancer Center, is now offering patients with advanced cancer a cutting-edge clinical test that will provide them with a unique blueprint of their cancer genes.

The new clinical test, known as CancerCode-45TM, evaluates an individual's tumor for genetic alterations in a select group of 45 genes and gives physicians the opportunity to look at the alterations and be even more precise when choosing a course of treatment. The test is being offered through the Cancer Genome Institute at Fox Chase -- one of only a few centers in the nation to offer such pioneering technology in cancer molecular diagnostics.

"Gaining insight like this into the DNA of a specific tumor is the next step in transforming cancer care and prevailing over cancer," says Michael V. Seiden, MD, PhD, president and CEO of Fox Chase. "We are very excited to be offering this innovative test at our Center and look forward to the ways it will enhance the care we provide our patients."

Using leading-edge technology, physicians and scientists at Fox Chase are able to perform the CancerCode-45 test and analyze the genetic information in the DNA of a patient's tumor to find changes that are crucial to supporting their cancer. This genetic analysis will examine multiple alterations in 45 cancer-related genes and provide a report to the patient's treating physician.

Prior to the CancerCode-45 test being performed, patients will need to see a Fox Chase physician to provide information about their background, medical history, current medications, and ability to perform daily activities. In addition, the physician will need to take a blood sample and a sample of the tumor (which can come from a previous surgery or biopsy that the patient might have had). It takes about 20 working days to get each patient's test results.

"Not every patient will benefit from this test, but for some it could very well change their entire course of treatment and significantly prolong their life," says Jeff Boyd, PhD, executive director of the Cancer Genome Institute at Fox Chase. "At the very least, the results may help physicians decide how to treat their patients with advanced cancer -- whether by suggesting they use a particular type of drug or not use a particular type of drug or by allowing them to take part in clinical trials of new medications guided by their tumor's genetic profile."

To learn more about this new clinical test, please call 1-888-FOX CHASE or (1-888-369-2427).

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

Link:
Cancer Genome Institute at Fox Chase among first to offer clinical blueprint of cancer genes

SAN FRANCISCO, Jan. 7, 2013 /PRNewswire/ --Second Genome announced today an initiative with the American Gut project to explore the connection between the human microbiome and type 2 diabetes. The cooperation will bring together American Gut's broad citizen science network for microbiome sample collection with Second Genome's efforts in identifying microbiome modulators and novel therapeutics. Second Genome has made an undisclosed donation to American Gut to subsidize specimen collection for participants with type 2 diabetes.

It is believed that the human microbiome plays an important role in the maintenance of good health, and that alterations to the balance of these microbial populations may have a negative impact on immunity and metabolism. American Gut has built the world's largest open-source, community driven effort to characterize the microbiomes of everyday people in order to understand the connections between environmental factors and microbiome changes.

"By working with the American Gut project and its preeminent group of microbiome scientists, we have the opportunity to accelerate the clinical impact of this citizen science effort to build the world's leading reference dataset of microbiomes," said Peter DiLaura, President and CEO of Second Genome. "Second Genome is focusing on patients with type 2 diabetes as one part of its effort to translate microbiome science into the discovery and development of microbiome modulators with therapeutic potential."

"Second Genome brings a special focus on tackling specific clinical questions, including the impact that changes in the human microbiome have in patients with type 2 diabetes," said Dr. Rob Knight, Associate Professor of Chemistry and Biochemistry at University of Colorado - Boulder and project lead for American Gut. "We are pleased to partner in this way with Second Genome and look forward to exciting new discoveries from this research."

About Second Genome

Second Genome brings microbiome science to the discovery and development of therapeutic products. The company has established a pipeline of microbiome modulators that impact infection, immunity and metabolic diseases. Second Genome's development pipeline is fueled by novel technologies for identifying, screening and scientifically validating product candidates and microbial biomarkers. Second Genome's technologies have been rigorously validated through partnerships with leading pharmaceutical and nutrition companies, as well as academic and governmental research institutions. Please visit http://www.secondgenome.com for more information.

The rest is here:
Second Genome Sponsors American Gut Initiative to Identify Links Between Type 2 Diabetes and the Human Microbiome